by | Apr 29, 2024 | Lupus Foundation of America, News & Events
In a new study, people with systemic lupus erythematosus (SLE) who developed the disease later in life exhibited notable clinical differences and lower disease activity, however they also have the lowest survival rate. A group of 845 people with SLE were studied for...
by | Apr 25, 2024 | Lupus Foundation of America, News & Events
In systemic lupus erythematosus (SLE), poor disease outcomes often occur in minoritized populations such as Black/African American or Hispanic/Latino populations, and socioeconomically disadvantaged populations. In a new study examining people with systemic lupus...
by | Apr 25, 2024 | Lupus Foundation of America, News & Events
Day-to-day life with lupus can be challenging and take a toll on your mental health. A study examined the prevalence of people with depression and systemic lupus erythematosus (SLE) and found depression was highly prevalent, but often undiagnosed. The study included...
by | Apr 23, 2024 | Lupus Foundation of America, News & Events
A first person has been dosed with the investigational therapy, AlloNK® (also known as AB-101) for treatment of lupus nephritis, (LN, lupus-related kidney disease). This is the first time a person in the US has received an allogeneic NK cell (natural killer cell, a...
by | Apr 20, 2024 | Lupus Foundation of America, News & Events
A new study published in Lupus Science & Medicine found a new diagnostic and disease activity monitoring biomarker for systemic lupus erythematosus (SLE) which could help understand pathogenesis, identify therapeutic targets, and guide clinical management. In the...
by | Apr 19, 2024 | Lupus Foundation of America, News & Events
The U.S. Food & Drug Administration has granted approval for a Phase 1 study to evaluate the safety and efficacy of investigational therapy, CB-010, for treatment of lupus nephritis (LN). The GALLOP study will begin by year-end and will also be evaluated for...